Company

Bank

Analyst

Coverage

Opinion

Wk chg

9/20 cls

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Stifel Nicolaus

Stephen Willey

Downgrade

Hold (from buy)

9%

$76.95

Willey downgraded but maintained his $70 target on the belief that risk/reward is fully priced in ahead of a Nov. 19 FDA advisory committee meeting and Feb. 28 PDUFA date for Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). Vimizim is a recombinant human N-acetylgalactosamine-6-sulfatase.

Bruker Corp. (NASDAQ:BRKR)

Wells Fargo

Tim Evans

Downgrade

Market perform (from market outperform)

-2%

$20.41

Evans downgraded but maintained his $19-$21 target, saying Bruker is "faced with a lengthy investment period to overhaul its systems and processes" and "investors may be baking in too much improvement too soon." Evans continues to believe the instrument supplier will execute on its operational turnaround in 3-5 years, but said investors may be underestimating the difficulty of driving change.

Omeros Corp. (NASDAQ:OMER)

Wedbush

Liana Moussatos

Price target

Outperform

41%

$7.16